DK0853480T3 - Anvendelse af en thienotriazolodiazepin til forøgelse af apolipoprotein A-I-niveauer - Google Patents

Anvendelse af en thienotriazolodiazepin til forøgelse af apolipoprotein A-I-niveauer

Info

Publication number
DK0853480T3
DK0853480T3 DK96930137T DK96930137T DK0853480T3 DK 0853480 T3 DK0853480 T3 DK 0853480T3 DK 96930137 T DK96930137 T DK 96930137T DK 96930137 T DK96930137 T DK 96930137T DK 0853480 T3 DK0853480 T3 DK 0853480T3
Authority
DK
Denmark
Prior art keywords
pct
levels
thienotriazolodiazepine
sec
date
Prior art date
Application number
DK96930137T
Other languages
Danish (da)
English (en)
Inventor
Herman Kempen
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of DK0853480T3 publication Critical patent/DK0853480T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DK96930137T 1995-09-09 1996-08-30 Anvendelse af en thienotriazolodiazepin til forøgelse af apolipoprotein A-I-niveauer DK0853480T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP95114163 1995-09-09
PCT/EP1996/003814 WO1997009048A1 (en) 1995-09-09 1996-08-30 Use of a thienotriazolodiazepine to increase apolipoprotein a-i levels

Publications (1)

Publication Number Publication Date
DK0853480T3 true DK0853480T3 (da) 2003-05-05

Family

ID=8219597

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96930137T DK0853480T3 (da) 1995-09-09 1996-08-30 Anvendelse af en thienotriazolodiazepin til forøgelse af apolipoprotein A-I-niveauer

Country Status (14)

Country Link
US (1) US5854238A (enExample)
EP (1) EP0853480B1 (enExample)
JP (1) JPH11512107A (enExample)
KR (1) KR19990044460A (enExample)
CN (1) CN1101680C (enExample)
AT (1) ATE230600T1 (enExample)
AU (1) AU725249B2 (enExample)
BR (1) BR9610390A (enExample)
CA (1) CA2230477A1 (enExample)
DE (1) DE69625696T2 (enExample)
DK (1) DK0853480T3 (enExample)
ES (1) ES2188783T3 (enExample)
TR (1) TR199800406T1 (enExample)
WO (1) WO1997009048A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004925A (en) * 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6518412B1 (en) * 1997-09-29 2003-02-11 Jean-Louis Dasseux Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6253569B1 (en) * 1999-05-07 2001-07-03 James J. Hall Portable storage unit for game animals
WO2003024441A1 (en) 2001-09-14 2003-03-27 Shionogi & Co., Ltd. Novel use of tricyclic compound
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US7144862B2 (en) 2000-08-24 2006-12-05 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US6664230B1 (en) 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7723303B2 (en) 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US7199102B2 (en) * 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7166578B2 (en) 2000-08-24 2007-01-23 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7148197B2 (en) * 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
US8124625B2 (en) 2001-09-14 2012-02-28 Shionogi & Co., Ltd. Method of enhancing the expression of apolipoprotein AI using olefin derivatives
US7429593B2 (en) 2001-09-14 2008-09-30 Shionogi & Co., Ltd. Utilities of amide compounds
US6930085B2 (en) * 2002-04-05 2005-08-16 The Regents Of The University Of California G-type peptides to ameliorate atherosclerosis
RU2414236C2 (ru) 2004-12-06 2011-03-20 Зе Риджентс Оф Зи Юнивесити Оф Кэлифонье Способ улучшения структуры и/или функций артериол
JP2010537638A (ja) 2007-08-28 2010-12-09 ユーエービー リサーチ ファウンデーション 合成アポリポ蛋白質ｅ模倣ポリペプチドおよび使用方法
AU2008296478B9 (en) 2007-08-28 2015-03-19 The Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
US8569288B2 (en) 2008-10-30 2013-10-29 Circomed Llc Thienotriazolodiazepine derivatives active on apo A
CN103119160B (zh) * 2010-05-14 2016-06-01 达那-法伯癌症研究所 用于调节代谢的组合物和方法
HUE031073T2 (en) 2010-05-14 2017-06-28 Dana Farber Cancer Inst Inc Thieno triazolo-diazepine compounds for the treatment of neoplasia
CA2799403C (en) 2010-05-14 2020-01-21 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating leukemia
WO2011143657A1 (en) 2010-05-14 2011-11-17 Dana-Farber Cancer Institute, Inc. Male contraceptive compositions and methods of use
KR20160034379A (ko) 2013-07-25 2016-03-29 다나-파버 캔서 인스티튜트 인크. 전사 인자의 억제제 및 그의 용도
RU2016122654A (ru) 2013-11-08 2017-12-14 Дана-Фарбер Кэнсер Инститьют, Инк. Комбинированная терапия злокачественной опухоли с использованием ингибиторов бромодоменового и экстратерминального (вет) белка
US10793571B2 (en) 2014-01-31 2020-10-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
US10150756B2 (en) 2014-01-31 2018-12-11 Dana-Farber Cancer Institute, Inc. Diaminopyrimidine benzenesulfone derivatives and uses thereof
CA2940472A1 (en) 2014-02-28 2015-09-03 Tensha Therapeutics, Inc. Treatment of conditions associated with hyperinsulinaemia
CA2954475C (en) 2014-07-31 2023-05-16 Uab Research Foundation Apoe mimetic peptides and higher potency to clear plasma cholesterol
EP3177147A4 (en) 2014-08-08 2018-01-24 Dana-Farber Cancer Institute, Inc. Dihydropteridinone derivatives and uses thereof
RU2017104897A (ru) 2014-08-08 2018-09-10 Дана-Фарбер Кэнсер Инститьют, Инк. Производные диазепана и их применения
EA033325B1 (ru) 2014-10-27 2019-09-30 Тэнша Терапеутикс, Инк. Ингибиторы бромодомена
CA2986441A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
KR20180051576A (ko) 2015-09-11 2018-05-16 다나-파버 캔서 인스티튜트 인크. 아세트아미드 티에노트리아졸로디아제핀 및 그의 용도
CN108472300A (zh) 2015-09-11 2018-08-31 达纳-法伯癌症研究所股份有限公司 氰基噻吩并三唑并二氮杂环庚三烯及其用途
PE20181298A1 (es) 2015-11-25 2018-08-07 Dana Farber Cancer Inst Inc Inhibidores de bromodominio bivalentes y usos de los mismos
JP2021527136A (ja) 2018-06-13 2021-10-11 ディブリー・アーゲー 縮合トリアゼピン誘導体の調製及びｂｅｔ阻害剤としてのその使用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4155913A (en) * 1973-02-08 1979-05-22 Hoffmann-La Roche Inc. Thienotriazolodiazepine derivatives
PH12303A (en) * 1973-02-08 1979-01-16 Hoffmann La Roche Thienotriazolodiazepine derivatives
JPS50100096A (enExample) * 1974-01-08 1975-08-08

Also Published As

Publication number Publication date
US5854238A (en) 1998-12-29
KR19990044460A (ko) 1999-06-25
EP0853480B1 (en) 2003-01-08
WO1997009048A1 (en) 1997-03-13
JPH11512107A (ja) 1999-10-19
CA2230477A1 (en) 1997-03-13
AU6930396A (en) 1997-03-27
BR9610390A (pt) 1999-07-06
MX9801753A (es) 1998-08-30
TR199800406T1 (en) 1998-05-21
AU725249B2 (en) 2000-10-12
ATE230600T1 (de) 2003-01-15
CN1101680C (zh) 2003-02-19
ES2188783T3 (es) 2003-07-01
DE69625696T2 (de) 2003-10-16
EP0853480A1 (en) 1998-07-22
CN1195989A (zh) 1998-10-14
DE69625696D1 (de) 2003-02-13

Similar Documents

Publication Publication Date Title
DK0853480T3 (da) Anvendelse af en thienotriazolodiazepin til forøgelse af apolipoprotein A-I-niveauer
TR199901276T2 (xx) Farnezil protein transferaz inhibisyonu i�in yararl� bile�ikler.
ES2142593T3 (es) Poliuretanos altamente funcionalizados.
ATE182892T1 (de) Mercaptoacetylamide von pyridazo(1,2-a>(1,2>- diazepin -derivaten als eukephalinase und ace- inhibitoren
EP0760658A4 (en) PREPARATIONS FOR INHIBITING BONE RESORPTION BROUGHT BY OSTEOCLASTIC
NZ324921A (en) Cathepsin K crystal structure and methods of identifying inhibitors of this protease
CA2174494A1 (en) Benzofurans
BR9609797A (pt) Inibição de expressão de gene
DK0865498T3 (da) Fremgangsmåde til fremstilling af substituerede arylmælkesyreholdige cyclodepsipeptider med 24 ringatomer
ZA964097B (en) New variant of apolipoprotein a-i
DE69616074D1 (de) Ara-c derivate
ATE244712T1 (de) Piperazino-derivative als neurokininantagonisten
IL122606A (en) (S)-hydroxa-nitrile-lyase
DK0804079T3 (da) Algicidkombination
NO20003397L (no) 3 '-epimerie K-252A-derivater
DE60031269D1 (de) Halbsynthese von paclitaxel mit hilfe von dialkyldichlorsilanen
DE69619530D1 (de) Zyklische somatostatinanaloge mit wachstumhormon inhibierender aktivität
SE9301831D0 (sv) Pharmaceutical compositions
DK0825859T3 (da) Anvendelse af forskolin eller ekstrakter indeholdende dette til fremstilling af et lægemiddel til behandling af alkoholafhængighed
PT971714E (pt) Metodo utilizando inibidores ciclooxigenase-2 no tratamento e prevencao da demencia
SE9500500D0 (sv) Inhibtion of the growth of E. coli
TR199901273T2 (xx) Farnezil protein transferaz inhibisyonu i�in yararl� bile�ikler.
BR9607577A (pt) Método para inibir catepsina k
FI954263A0 (fi) Vid skjutning anvaendbart foerfarande foer bestaemning av traeffar
IT1281069B1 (it) Preparazione di metossimetilmelammine.